Walgreens Boots Alliance Inc
Change company Symbol lookup
Select an option...
WBA Walgreens Boots Alliance Inc
HBI HanesBrands Inc
TMKR Tastemaker Acquisition Corp
SPY SPDR® S&P 500 ETF Trust
STOR STORE Capital Corp
PIPP^ Pine Island Acquisition Corp
PEP PepsiCo Inc
$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid Cap
PNM PNM Resources Inc
CBLAQ CBL & Associates Properties Inc

Consumer Staples : Food & Staples Retailing | Mid Cap Value
Company profile

Walgreens Boots Alliance, Inc., is a holding company. The Company is a pharmacy-led health and wellbeing company. The Company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment consists of the Walgreen Co. (Walgreens) business, which includes the operation of retail drugstores, care clinics and providing specialty pharmacy services. The Retail Pharmacy International segment consists primarily of the Alliance Boots pharmacy-led health and beauty stores, optical practices and related contract manufacturing operations. The Pharmaceutical Wholesale segment consists of the Alliance Boots pharmaceutical wholesaling and distribution businesses. The Company's portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as global health and beauty product brands, including No7, Botanics, Liz Earle and Soap & Glory.

Closing Price
Day's Change
0.34 (0.73%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Walgreens stock rises after adjusted earnings, sales beat expectations

7:26 am ET January 7, 2021 (MarketWatch)

Walgreens Boots Alliance Inc. (WBA) stock rose 4% in Thursday premarket trading after the pharmacy retailer reported fiscal first quarter adjusted earnings per share and sales that beat the Street. Walgreens reported a net loss of $308.0 million, or 36 cents per share, after net income of $845.0 million, or 95 cents per share, a year ago. Adjusted EPS fell 11.2% year-over-year to $1.22, but beat the FactSet consensus for $1.03. Adjusted EPS included a COVID-19 impact of 26 cents to 30 cents per share. Sales of $36.3 billion were up from $34.3 billion a year ago, and ahead of the FactSet consensus for $34.9 billion. Retail pharmacy sales in the U.S. totaled $27.2 billion, up 3.9% from the previous year. Same-store sales rose 3.7%, and prescriptions filled increased 2.7% in comparable stores. Total prescriptions filled were up 1.1%. Retail pharmacy international sales were $2.6 billion, down 6.2% year-over-year. Walgreens maintained its fiscal 2021 guidance for adjusted EPS to grow in the low-single digits. The FactSet consensus is for EPS of $4.81, suggesting 1.5% growth. Walgreens announced Wednesday that it sold the majority of its Alliance Healthcare pharmacy (http://www.marketwatch.com/story/walgreens-sells-majority-of-alliance-healthcare-pharmacy-business-to-amerisourcebergen-in-6-5-billion-deal-11609938196) business to AmerisourceBergen Corp. (ABC) Walgreens shares have slumped 27.4% over the last year while the benchmark S&P 500 index has gained 15.8% for the period.

-Tonya Garcia; 415-439-6400; AskNewswires@dowjones.com


(END) Dow Jones Newswires

January 07, 2021 07:26 ET (12:26 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.